Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory Briefs: What's New From FDA

This article was originally published in The Gray Sheet

Executive Summary

Medtronic gets February panel date for its DIAM spine device, which would be the firm's second interspinous spacer on the market; FDA moves risk classifications forward for five device types; and the agency continues its scrutiny of direct-to-consumer genetic tests.

You may also be interested in...



After Years Of Waiting, FDA Classifies Anthrax Detection Devices As Class II

A new guidance document and final rule from US FDA on Bacillus bacteria detection devices, which are used to diagnose anthrax, place the pre-amendment devices in class II.

US FDA Shelves Proposal To Mandate Home-Use Device E-Labeling

A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.

Ortho Panel Green Lights VertiFlex’s Superion Spine Spacer

A majority of FDA advisors say the device intended to treat lumbar spinal stenosis has a positive risk-benefit profile but should require an extended postmarket trial to evaluate its safety and efficacy over a longer time period.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel